ACAD ACADIA Pharmaceuticals Inc. Stock Quote

publish chart | save to portfolio | create alert

Settings

ACAD [NASD]

ACADIA Pharmaceuticals Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	0.27%	Shs Outstand	158.13M	Perf Week	4.46%
Market Cap	8.88B	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-23.07%	Shs Float	116.72M	Perf Month	20.64%
Income	-267.90M	PEG	-	EPS next Q	-0.47	Inst Own	96.80%	Short Float	6.85%	Perf Quarter	47.45%
Sales	419.10M	P/S	21.19	EPS this Y	17.50%	Inst Trans	-0.93%	Short Ratio	7.73	Perf Half Y	14.54%
Book/sh	4.14	P/B	13.53	EPS next Y	47.30%	ROA	-34.70%	Target Price	59.61	Perf Year	19.15%
Cash/sh	4.06	P/C	13.78	EPS next 5Y	25.00%	ROE	-40.30%	52W Range	30.02 - 58.72	Perf YTD	30.90%
Dividend	-	P/FCF	-	EPS past 5Y	-10.90%	ROI	-35.40%	52W High	-4.63%	Beta	1.46
Dividend %	-	Quick Ratio	7.90	Sales past 5Y	390.00%	Gross Margin	95.10%	52W Low	86.54%	ATR	1.88
Employees	580	Current Ratio	7.90	Sales Q/Q	27.50%	Oper. Margin	-65.80%	RSI (14)	76.21	Volatility	2.92% 3.85%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-86.10%	Profit Margin	-63.90%	Rel Volume	0.48	Prev Close	56.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 04 AMC	Payout	-	Avg Volume	1.03M	Price	56.00
Recom	1.60	SMA20	8.93%	SMA50	21.80%	SMA200	24.46%	Volume	0	Change	0.00%

Nov-16-20

Upgrade

Raymond James

Outperform → Strong Buy

$65

Aug-25-20

Initiated

Raymond James

Outperform

$65

Aug-20-20

Initiated

Morgan Stanley

Overweight

$55

Jul-07-20

Upgrade

Stifel

Hold → Buy

$41 → $71

Apr-16-20

Initiated

Jefferies

Buy

$60

Mar-31-20

Upgrade

Goldman

Neutral → Buy

$45 → $72

Mar-06-20

Initiated

Citigroup

Buy

$69

Dec-16-19

Initiated

Guggenheim

Buy

$60

Oct-24-19

Initiated

Oppenheimer

Perform

$44

Oct-01-19

Initiated

RBC Capital Mkts

Outperform

$60

Sep-13-19

Upgrade

SVB Leerink

Mkt Perform → Outperform

Sep-10-19

Upgrade

Canaccord Genuity

Hold → Buy

$29 → $50

Jul-23-19

Reiterated

Needham

Buy

$40 → $34

Dec-10-18

Initiated

Canaccord Genuity

Hold

$23

Sep-21-18

Upgrade

Piper Jaffray

Neutral → Overweight

Aug-09-18

Reiterated

Stifel

Hold

$17 → $14

Aug-07-18

Initiated

Stifel

Hold

$17

Aug-06-18

Downgrade

Piper Jaffray

Overweight → Neutral

Oct-06-17

Resumed

Goldman

Neutral

Nov-11-16

Initiated

Goldman

Neutral

Nov-24-20 11:21PM	ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit Simply Wall St.
Nov-11-20 03:15AM	These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden MarketWatch
Nov-10-20 09:00AM	Acadia Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 Business Wire
Nov-05-20 12:45PM	ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y Zacks
06:07AM	What's Behind Acadia Pharmaceuticals' Mixed Q3 Results Motley Fool
Nov-04-20 05:55PM	Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates Zacks +5.43%
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results Business Wire
02:30PM	ACADIA Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 12:32PM	Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline Zacks
Oct-26-20 10:02PM	Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)? Insider Monkey
09:00AM	Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference Business Wire
Oct-21-20 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2020 Financial Results on November 4, 2020 Business Wire
Oct-14-20 04:05PM	The Lewy Body Dementia Association and Acadia Pharmaceuticals to Release Educational Version of the Highly Acclaimed Robin Williams Documentary, "Robins Wish" Business Wire
Oct-01-20 09:00AM	Acadia Pharmaceuticals Appoints Elizabeth Garofalo, M.D. to Board of Directors Business Wire
Sep-07-20 05:15PM	Hedge Funds Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Sep-05-20 08:47AM	(ACAD) Alert: Johnson Fistel Announces Shareholder Class Action Against ACADIA Pharmaceuticals Survives Motion to Dismiss; Should Management be Held Accountable for Investors Losses? PR Newswire
Sep-04-20 11:31AM	Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound? Zacks
Sep-02-20 09:00AM	ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-31-20 09:00AM	ACADIA Pharmaceuticals Appoints Gudarz Davar, M.D., as Executive Vice President and Head of Research and Development Business Wire
Aug-26-20 10:44PM	5 Biotech Stocks That Could Be Worth a Look Barrons.com
01:01PM	ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio Zacks
Aug-25-20 09:35AM	Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga
09:00AM	ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio Business Wire
Aug-24-20 07:08AM	What Does ACADIA Pharmaceuticals' (NASDAQ:ACAD) CEO Pay Reveal? Simply Wall St.
Aug-23-20 11:33AM	Morgan Stanley Is Getting Bullish About Biotech; Here Are 2 Stocks to Buy TipRanks
Aug-20-20 09:51AM	Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga
Aug-12-20 09:00AM	ACADIA Pharmaceuticals to Present at The JMP Securities CNS Forum on August 19, 2020 Business Wire
Aug-06-20 01:19PM	ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales Zacks
Aug-05-20 06:25PM	Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results Business Wire
Jul-31-20 08:00PM	SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD) Newsfile
Jul-30-20 03:37PM	SHAREHOLDER ALERT: Stephens & Stephens LLP Investigating the Officers and Directors of ACADIA Pharmaceuticals Inc. (ACAD) Business Wire
Jul-29-20 12:33PM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
09:00AM	People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights Business Wire
Jul-28-20 11:33AM	ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-22-20 04:05PM	ACADIA Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020 Business Wire
12:32PM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-21-20 04:24PM	Acadia Pharma Dives On Unexpected Flop In Depression Treatment Investor's Business Daily -19.36%
03:46AM	Acadia Plunges 12% As Depressive Study Misses Goals; Analyst Says Buy SmarterAnalyst
Jul-20-20 05:30PM	U.S. FDA accepts Acadia's application for dementia drug Reuters
04:03PM	ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Business Wire
04:02PM	ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Business Wire
Jul-12-20 08:54PM	Did Hedge Funds Make The Right Call On ACADIA Pharmaceuticals Inc. (ACAD) ? Insider Monkey
Jul-08-20 06:51AM	Shareholders Are Thrilled That The ACADIA Pharmaceuticals (NASDAQ:ACAD) Share Price Increased 113% Simply Wall St.
Jul-07-20 10:42AM	Why Acadia Pharmaceuticals (ACAD) Stock is a Compelling Investment Case Insider Monkey +6.17%
Jun-29-20 03:50PM	Biotech Could Burst Higher, Says Signal Schaeffer's Investment Research
Jun-17-20 07:36PM	3 Strong Buy Healthcare Stocks That Should Remain Healthy TipRanks
Jun-16-20 10:47AM	ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis Zacks
06:00AM	Acadia Files Nuplazid Label Expansion; Analyst Sees Significant Potential SmarterAnalyst
Jun-15-20 09:00AM	ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis Business Wire
Jun-08-20 03:37AM	Hedge Funds Are Selling ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Jun-06-20 11:31AM	Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report? Zacks
Jun-02-20 09:00AM	ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020 Business Wire
07:27AM	Is Acadia Pharmaceuticals a Buy? Motley Fool
May-28-20 09:00AM	ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer Business Wire
May-27-20 12:15PM	ACADIA to Merge Two Phase III Studies on Nuplazid for MDD Zacks
May-26-20 09:00AM	ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Business Wire
May-21-20 11:28PM	Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
09:00AM	ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting Business Wire
May-09-20 08:02AM	Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) First-Quarter Report Simply Wall St.
May-08-20 10:31PM	Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript Motley Fool
10:55AM	ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates Zacks
May-07-20 06:10PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:06PM	ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results Business Wire
04:05PM	ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration Business Wire
May-05-20 04:05PM	ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences Business Wire
Apr-30-20 12:34PM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-15-20 04:05PM	ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020 Business Wire
Apr-13-20 09:43AM	We're Not Worried About ACADIA Pharmaceuticals's (NASDAQ:ACAD) Cash Burn Simply Wall St.
Mar-27-20 11:31AM	Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report? Zacks
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +8.74%
Mar-22-20 05:04PM	Largest Insider Trades of the Week GuruFocus.com
Mar-20-20 02:11PM	Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Mar-17-20 12:06AM	Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +8.63%
Mar-03-20 05:50PM	ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome Business Wire
Feb-28-20 08:35PM	Dont Expect Virgin Galactic Shares to Keep Rocketing Upward Barrons.com +9.31%
01:54PM	ACADIA Pharmaceuticals Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-27-20 11:13AM	ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales Zacks
Feb-26-20 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-24-20 09:00AM	ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020 Business Wire -6.38%
Feb-19-20 12:31PM	Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-12-20 09:00AM	ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020 Business Wire
Feb-05-20 06:13AM	Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
Jan-29-20 05:00AM	ACADIA- From Depression to Schizophrenia MoneyShow
Jan-17-20 08:45AM	ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-10-20 11:54AM	How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 09:00AM	ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 Business Wire
Dec-23-19 02:47PM	Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
11:30AM	Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year? Zacks
Dec-22-19 07:12AM	Can You Imagine How Chuffed ACADIA Pharmaceuticals's (NASDAQ:ACAD) Shareholders Feel About Its 215% Share Price Gain? Simply Wall St.
Dec-19-19 10:18AM	Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
Dec-18-19 04:05PM	ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer Business Wire -5.81%
Dec-17-19 09:11AM	5 Biotech Stocks That Have More Than Doubled This Year Zacks
Dec-12-19 11:56AM	The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM	5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-06-19 07:39AM	The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
05:00AM	A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know Barrons.com
Dec-05-19 11:01PM	Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally Insider Monkey +14.00%
04:08PM	Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone Investor's Business Daily

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stankovic Srdjan R.	President	Nov 20	Sale	53.50	2,728	145,948	16,528	Nov 20 09:29 PM
KIM AUSTIN D.	EVP & General Counsel	Oct 27	Option Exercise	17.58	8,750	153,825	12,601	Oct 29 04:12 PM
KIM AUSTIN D.	EVP & General Counsel	Oct 27	Sale	45.10	8,750	394,636	3,851	Oct 29 04:12 PM
YANG MICHAEL J.	EVP and CCO	Oct 16	Sale	42.56	1,247	53,072	6,457	Oct 19 05:27 PM
Stankovic Srdjan R.	President	Oct 16	Sale	42.56	1,297	55,200	13,006	Oct 19 05:26 PM
DAVIS STEPHEN	CEO	Oct 16	Sale	42.56	2,960	125,978	14,786	Oct 19 05:25 PM
YANG MICHAEL J.	EVP and CCO	Jul 07	Option Exercise	23.00	27,250	626,770	32,454	Jul 09 06:26 PM
YANG MICHAEL J.	EVP and CCO	Jul 07	Sale	56.25	27,250	1,532,786	5,204	Jul 09 06:26 PM
Stankovic Srdjan R.	President	Jun 19	Option Exercise	18.12	16,452	298,110	27,786	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 19	Sale	50.12	16,452	824,515	11,334	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 18	Option Exercise	18.81	65,843	1,238,697	77,177	Jun 19 06:55 PM
Stankovic Srdjan R.	President	Jun 18	Sale	50.01	65,843	3,292,729	11,334	Jun 19 06:55 PM
DAVIS STEPHEN	CEO	May 14	Option Exercise	19.65	88,542	1,739,850	100,351	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 14	Sale	45.62	88,542	4,039,105	11,809	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 13	Option Exercise	19.65	111,458	2,190,150	123,267	May 15 07:11 PM
DAVIS STEPHEN	CEO	May 13	Sale	46.35	111,458	5,165,587	11,809	May 15 07:11 PM
Daly James M	Director	May 11	Option Exercise	26.39	26,250	692,700	26,250	May 13 06:00 PM
Daly James M	Director	May 11	Sale	51.13	26,250	1,342,178	0	May 13 06:00 PM
Stankovic Srdjan R.	President	Apr 30	Sale	49.21	4,308	211,997	11,334	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 30	Sale	49.22	1,050	51,681	2,195	May 01 06:00 PM
DAVIS STEPHEN	CEO	Apr 30	Sale	49.21	6,770	333,152	11,809	May 01 06:00 PM
YANG MICHAEL J.	EVP and CCO	Apr 30	Sale	49.21	1,501	73,864	5,204	May 01 06:00 PM
KIM AUSTIN D.	EVP & General Counsel	Apr 30	Sale	49.22	1,072	52,764	2,441	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 29	Option Exercise	25.12	10,000	251,200	10,000	May 01 06:00 PM
Ridloff Elena	EVP and CFO	Apr 29	Sale	50.74	10,000	507,353	0	May 01 06:00 PM
Stankovic Srdjan R.	President	Apr 23	Option Exercise	20.67	18,949	391,704	24,976	Apr 24 06:00 PM
Stankovic Srdjan R.	President	Apr 23	Sale	50.07	18,949	948,729	6,027	Apr 24 06:00 PM
Stankovic Srdjan R.	President	Apr 22	Option Exercise	19.77	54,019	1,067,956	60,046	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 22	Sale	50.02	54,019	2,701,906	6,027	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 20	Option Exercise	19.65	100,000	1,965,000	106,027	Apr 22 06:30 PM
Stankovic Srdjan R.	President	Apr 20	Sale	50.15	100,000	5,015,450	6,027	Apr 22 06:30 PM
BAKER BROS. ADVISORS LP	Director	Mar 18	Buy	33.52	135,897	4,555,101	38,433,977	Mar 18 06:47 PM
BAKER BROS. ADVISORS LP	Director	Mar 17	Buy	32.84	219,800	7,218,907	38,309,339	Mar 18 06:47 PM
BAKER BROS. ADVISORS LP	Director	Mar 16	Buy	31.51	694,303	21,878,017	38,107,749	Mar 18 06:47 PM
Brege Laura	Director	Jan 07	Option Exercise	1.75	10,000	17,500	10,000	Jan 08 06:01 PM
Brege Laura	Director	Jan 07	Sale	42.19	10,000	421,900	0	Jan 08 06:01 PM
YANG MICHAEL J.	EVP and CCO	Dec 12	Option Exercise	31.09	105,479	3,279,377	107,978	Dec 13 05:35 PM
YANG MICHAEL J.	EVP and CCO	Dec 12	Sale	44.46	105,479	4,689,263	2,499	Dec 13 05:35 PM
KIM AUSTIN D.	EVP & General Counsel	Dec 11	Option Exercise	17.58	17,500	307,650	18,009	Dec 13 05:34 PM
KIM AUSTIN D.	EVP & General Counsel	Dec 11	Sale	45.06	17,500	788,576	509	Dec 13 05:34 PM
Ridloff Elena	EVP and CFO	Dec 09	Option Exercise	15.81	36,000	569,160	36,000	Dec 11 06:29 PM
YANG MICHAEL J.	EVP and CCO	Dec 09	Option Exercise	35.86	14,521	520,723	16,144	Dec 11 06:30 PM
YANG MICHAEL J.	EVP and CCO	Dec 09	Sale	50.46	14,521	732,792	1,623	Dec 11 06:30 PM
Ridloff Elena	EVP and CFO	Dec 09	Sale	49.66	36,000	1,787,853	0	Dec 11 06:29 PM
DAVIS STEPHEN	CEO	Dec 05	Option Exercise	19.65	150,000	2,947,500	152,954	Dec 06 06:25 PM
DAVIS STEPHEN	CEO	Dec 05	Sale	52.34	150,000	7,851,300	2,954	Dec 06 06:25 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience